Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

41.32USD
23 Jul 2019
Change (% chg)

$0.19 (+0.46%)
Prev Close
$41.13
Open
$41.42
Day's High
$41.49
Day's Low
$41.26
Volume
2,453,110
Avg. Vol
2,380,160
52-wk High
$42.20
52-wk Low
$36.41

Latest Key Developments (Source: Significant Developments)

GSK Poised To Name Jonathan Symonds As Its Next Chairman- Bloomberg
Sunday, 14 Jul 2019 02:24pm EDT 

July 14 (Reuters) - :GLAXOSMITHKLINE PLC IS POISED TO NAME JONATHAN SYMONDS AS ITS NEXT CHAIRMAN- BLOOMBERG, CITING A SOURCE.  Full Article

GSK Says ViiV Switch Study Shows 2DR As Effective As 3DR
Wednesday, 10 Jul 2019 02:00am EDT 

July 10 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - VIIV SWITCH STUDY SHOWS 2DR AS EFFECTIVE AS 3DR.GLAXOSMITHKLINE PLC - PHASE III HIV STUDY MEETS PRIMARY ENDPOINT.GSK- STUDY SHOWED ABILITY TO CONTROL HIV-1 WITH REGIMEN OF DOLUTEGRAVIR+LAMIVUDINE IN VIRALLY SUPPRESSED PATIENTS SWITCHING FROM 3-DRUG REGIMEN.GLAXOSMITHKLINE PLC - STUDY MET ITS PRIMARY ENDPOINT FOR NON-INFERIORITY.GLAXOSMITHKLINE PLC - SAFETY RESULTS FOR 2DR OF DOLUTEGRAVIR PLUS LAMIVUDINE WERE CONSISTENT WITH PRODUCT LABELLING FOR MEDICINES.GSK - NO PATIENTS MET CONFIRMED VIROLOGIC WITHDRAWAL CRITERIA OR DEVELOPED TREATMENT RESISTANCE IN DOLUTEGRAVIR PLUS LAMIVUDINE ARM OF STUDY.  Full Article

Springworks Therapeutics Announces Global Clinical Collaboration With GlaxoSmithKline
Thursday, 27 Jun 2019 06:30am EDT 

June 27 (Reuters) - :SPRINGWORKS THERAPEUTICS ANNOUNCES GLOBAL CLINICAL COLLABORATION WITH GLAXOSMITHKLINE TO EVALUATE NIROGACESTAT IN COMBINATION WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.SPRINGWORKS - GLAXOSMITHKLINE WILL SPONSOR & CONDUCT ADAPTIVE PHASE 1B STUDY TO EVALUATE SAFETY, TOLERABILITY & PRELIMINARY EFFICACY OF COMBINATION.SPRINGWORKS THERAPEUTICS - GLAXOSMITHKLINE WILL ASSUME ALL DEVELOPMENT COSTS ASSOCIATED WITH STUDY.SPRINGWORKS THERAPEUTICS - GLAXOSMITHKLINE, CO WILL ALSO FORM JOINT DEVELOPMENT COMMITTEE TO MANAGE CLINICAL STUDY.  Full Article

Liquidia And Gsk Restructure Collaboration Agreement
Wednesday, 26 Jun 2019 05:06pm EDT 

June 26 (Reuters) - GlaxoSmithKline PLC ::LIQUIDIA AND GSK RESTRUCTURE COLLABORATION AGREEMENT.LIQUIDIA - AMENDED AGREEMENT PROVIDES COMPANY WITH THE RIGHT TO DEVELOP AND COMMERCIALIZE THREE ADDITIONAL PRINT-BASED THERAPEUTICS.LIQUIDIA TECHNOLOGIES - CAN BUY RIGHTS TO PURSUE ADDITIONAL PRINT-BASED PROGRAMS FOR INHALATION THERAPY, SUBJECT TO GSK'S APPROVAL.LIQUIDIA TECHNOLOGIES - ANY NEW PRINT-BASED THERAPEUTIC DELIVERED VIA INHALATION DEVELOPED BY CO WOULD CARRY MILESTONE & ROYALTY OBLIGATIONS DUE TO GSK.LIQUIDIA- AMENDED DEAL PROVIDES GSK WITH RIGHT OF FIRST NEGOTIATION PRIOR TO CO ENTERING INTO LICENSE DEAL WITH 3RD PARTY FOR ANY GSK-APPROVED PROGRAM.LIQUIDIA - ANY NEW PRINT-BASED THERAPEUTIC DELIVERED VIA INHALATION DEVELOPED BY CO UNDER AMENDED DEAL WOULD CARRY MILESTONE, ROYALTY OBLIGATIONS DUE.  Full Article

GSK Says FDA Accepts Application For Zejula In Ovarian Cancer With Priority Review
Monday, 24 Jun 2019 07:12am EDT 

June 24 (Reuters) - GlaxoSmithKline PLC ::SAYS U.S. FDA ACCEPTS APPLICATION FOR ZEJULA (NIRAPARIB) IN LATE STAGE OVARIAN CANCER WITH PRIORITY REVIEW.SAYS THE SUPPLEMENTAL NEW DRUG APPLICATION FOR ZEJULA (NIRAPARIB) HAS AN ACTION DATE OF 24 OCTOBER 2019.  Full Article

GSK Says Nucala (Mepolizumab) Gains U.S. FDA Approval For Two New Self-Administration Options
Thursday, 6 Jun 2019 03:52pm EDT 

June 6 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE SAYS NUCALA (MEPOLIZUMAB) GAINS U.S. FDA APPROVAL FOR TWO NEW SELF-ADMINISTRATION OPTIONS.  Full Article

Glaxosmithkline Gets CHMP Positive On Nucala Self-Administration
Tuesday, 4 Jun 2019 03:00am EDT 

June 4 (Reuters) - GlaxoSmithKline PLC ::CHMP POSITIVE ON GSK'S NUCALA SELF-ADMINISTRATION.NUCALA (MEPOLIZUMAB) RECEIVES POSITIVE CHMP OPINION FOR NEW SELF-ADMINISTRATION OPTIONS.ORIGINAL LYOPHILISED POWDER VERSION REMAINS AVAILABLE FOR ADMINISTRATION IN CLINIC BY A HEALTHCARE PROFESSIONAL.  Full Article

GSK Gets Approval Of Shingrix In China In Adults Aged 50 And Over
Thursday, 23 May 2019 12:06pm EDT 

May 23 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE - GSK ANNOUNCES APPROVAL OF SHINGRIX IN CHINA FOR PREVENTION OF SHINGLES IN ADULTS AGED 50 AND OVER.GLAXOSMITHKLINE - EXPECTS TO INCREASE SUPPLY OF SHINGRIX GLOBALLY AND IS INVESTING IN SIGNIFICANT CAPACITY EXPANSION.  Full Article

GSK Changes Sales Representative Incentive Programme
Thursday, 23 May 2019 09:04am EDT 

May 23 (Reuters) - GlaxoSmithKline PLC ::STATEMENT: GSK CHANGES SALES REPRESENTATIVE INCENTIVE PROGRAMME.GLAXOSMITHKLINE - ANNOUNCING CHANGES TO INCENTIVE PROGRAMME FOR SALES REPRESENTATIVES IN CERTAIN COUNTRIES.GLAXOSMITHKLINE PLC - CHANGES REFLECT GROWING SHIFT IN GSK'S PORTFOLIO TO INNOVATIVE SPECIALTY CARE PRODUCTS, INCLUDING ONCOLOGY.GSK - CHANGES TO BE MADE TO INCENTIVE PROGRAMME FOR PHARMACEUTICAL, VACCINES SALES REPRESENTATIVES TO "BETTER RECOGNISE & REWARD INDIVIDUAL EFFORT".GSK- IN SPECIALTY CARE, CAPPED VARIABLE PAY ELEMENT OF A SALES REPRESENTATIVE'S COMPENSATION WILL BE EVALUATED ON BASIS OF INDIVIDUAL SALES TARGETS.GSK - CHANGES TO INCENTIVE PROGRAMME WILL BE APPLIED INITIALLY IN US, UK AND CANADA FROM JULY 2019.  Full Article

Australian competition regulator Not To Oppose GSK's Proposed Acquisition Of Pfizer's Consumer Healthcare Business In Australia
Wednesday, 8 May 2019 08:56pm EDT 

May 9 (Reuters) - Australian Competition and Consumer Commission::WILL NOT OPPOSE GSK’S PROPOSED ACQUISITION OF PFIZER’S CONSUMER HEALTHCARE BUSINESS IN AUSTRALIA.ACCC CONSIDERS THAT TRANSACTION WILL NOT SUBSTANTIALLY LESSEN COMPETITION IN ANY MARKET IN AUSTRALIA.  Full Article

Swiss agree to extradite Chinese scientist to U.S. on theft charges

ZURICH Switzerland has agreed to extradite a Chinese researcher to the United States where prosecutors have charged him with helping his scientist sister steal secrets allegedly worth $550 million from British drugmaker GlaxoSmithKline.